Hematology

Review top news and interview highlights from the week ending July 15, 2022.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Verve Therapeutics is currently conducting a clinical trial in New Zealand and expects to be able to open trials in the UK and US later in 2022.

A second cohort has been dosed with 7.7e11 vg/kg to hopefully confirm the dose for phase 3 trials.

Legend Biotech seeks to prioritize other product candidates in its pipeline.

The senior director and clinical program leader, Translational Clinical Oncology at Novartis Institutes for BioMedical Research, discussed new data from the phase 1 study.

The professor of medicine and University of Minnesota Medical School discussed the advantages and unmet needs of natural killer cells in oncology.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The associate professor at Fred Hutch Cancer Center discussed data presented at the EHA 2022 Congress.

Review top news and interview highlights from the week ending July 1, 2022.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Michael Parini, chief executive officer and director, Freeline Therapeutics, discussed the company’s pipeline and mission.

A clinical trial evaluating MB-106 in WM is planned under Mustang Bio's new IND.

The chief of the lymphoma division and oncologist at Levine Cancer Institute discussed data from real-world experience studies.

The approval builds off of liso-cel's (Breyanzi) previous indication for third-line or later treatment in LBCL.

Review top news and interview highlights from the week ending June 24, 2022.

BioMarin received a positive CHMP opinion after the FDA delayed val-rox's BLA filing for the second time.

The director of the Pediatric Hemophilia and Coagulation Disorders Program at CS Mott Children’s Hospital discussed common challenges with gene therapy clinical trials.

The clinical professor of medicine, Helen Diller Family Comprehensive Cancer Center, UCSF, discussed cilta-cel and upcoming cell therapies.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Long term survival was limited and all patients with B-cell acute lymphoblastic leukemia eventually relapsed.

Annualized bleeding rate fell to 0 at a median of 58 weeks after infusion.

Jennifer Buell, PhD, president and chief executive officer, MiNK Therapeutics, discussed different indications for the iNKT therapy AgenT-797.

ACE1831 will soon be evaluated in a phase 1, first-in-human, clinical trial.

Oncologist discuss the possibility of earlier-line CAR T-cell therapies in MM.